{
    "nct_id": "NCT02910219",
    "official_title": "Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel With or Without Carboplatin: HALT-D",
    "inclusion_criteria": "1. Willing and able to provide written informed consent;\n2. Men and women ≥18 years of age;\n3. Pathologically confirmed diagnosis of HER2 positive breast cancer of any stage (previous treatment is allowed without limits on lines of prior therapy);\n4. Scheduled to receive at least 3 consecutive cycles of THP or TCHP;\n5. Performance status of 0-2 according to the ECOG scale;\n6. Negative pregnancy test at time of informed consent for women of childbearing potential;\n7. Able to read, understand, follow the study procedure and complete crofelemer, rescue medication, and bowel movement diaries;\n8. Patients may enroll simultaneously on this study and other studies, including but not limited to NSABP B52;\n9. Patients with brain metastases (including concurrent steroid treatment) are allowed on this study.\n10. Left Ventricular Ejection Fraction (LVEF) greater or equal to 50% at baseline as determined by either ECHO or MUGA\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Pregnant and/or breastfeeding;\n2. Ongoing irritable bowel syndrome (IBS) or colitis (including but not limited to ulcerative colitis, Crohn's disease, microscopic colitis, etc.);\n3. Use of investigational drugs within 3 weeks of signing consent or foreseen use during the study;\n4. Use of chemotherapy, trastuzumab, or pertuzumab within the past 3 weeks;\n5. Use of antibiotics within the past 7 days (up to 2 prophylactic doses of antibiotics for procedures including, but not limited to port placement, is permitted);\n6. Any type of ostomy;\n7. Total colectomy;\n8. Fecal incontinence;\n9. Ongoing radiation induced diarrhea or constipation or planned radiotherapy to the abdomen or pelvis while on study;\n10. Active systemic infection requiring ongoing intervention, including but not limited to oral and intravenous antibiotics, anti-fungals, anti-parasites, anti-virals;\n11. Abdominal or pelvic surgery without recovery of bowel function;\n12. Inadequate organ function for starting THP or TCHP, which may include the following laboratory results within 28 days prior to signing consent:\n\n    1. Total bilirubin > upper limit of normal (ULN) (unless the patient has documented Gilbert's syndrome)\n    2. Serum creatinine > 2.0 mg/dL or 177 μmol/L\n    3. AST (SGOT) and ALT (SPGT) > 2.5 ULN.",
    "miscellaneous_criteria": ""
}